*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Implement targeted therapies for acute myeloid leukemia.
Implement targeted therapies for diffuse large B-cell lymphoma?
Assess next steps in CAR-T cell therapies?
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA=Not Applicable
54321NA
Antigen Specific T-cell Therapies - From Targeting Viruses to AML - Catherine Bollard, M.D.
LYT-200, an Anti-Galectin-9 Antibody, for Treatment of AML/high-risk MDS - Aleksandra Filipovic M.D. Ph.D.
Novel Approaches to Treat AML Relapse Post Allo SCT - Guenther Koehne, M.D., Ph.D.
AI in Oncology - Siddhartha Mukherjee, M.D.
The Role of Intestinal Microbiome in Cancer Immunotherapy - Marcel van den Brink, M.D., Ph.D.
Uncoupling GVL and GVH - Déjà Vu All Over Again? - Robert Soiffer, M.D.
Is PTCy The Current Standard for GvHD Prophylaxis for Matched and Mismatched Unrelated Transplants? - Leo Luznik, M.D.
Novel Approaches to GVHD Prevention and Therapy - Corey Cutler, M.D.
*
*
*
*
*
*
*
*